PAX6 and neoplasm: Additionally, that study verified that PAX6 could predict the metachronous hepatic metastasis-free survival of patients with postoperative Pan-NENs more accurately than conventional histologic risk factors, included in the 2017 WHO classification such as the Ki-67 proliferative index, mitotic count, and level of tumor differentiation [22].